JNJ Johnson & Johnson
Johnson & Johnson (JNJ) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 6 comparable calls have settled; 33.3% reached the published sell target. Information only, not financial advice.
Mid-channel, rising on both timeframes
Price is between the two trend lines. Nothing to act on yet.
The next few months are read from the last 12 months, not the last 9 months: that channel fits this stock's recent turns at least as well (78% against 85%) and it is the one price is respecting now. The last 9 months stay as context: rising, +35% a year. The target of US$272.98 is below the nearest ceiling (US$288.23), so it does not depend on a breakout. What would overturn this: a close below US$241.91 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 9 months read from
- US$242.05 – US$288.23 Rising channel, +35% a year
- Position in that channel
- 50% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
We replayed these rules over this stock's own history and the target was reached on only 2 of 6 calls. Its swings do not respect the channel reliably enough for a published call, and no alerts are sent. The numbers below are still this site's read of the fitted channel.
Buy at or below
US$257.52
level as at 27 Oct 2026
Our target
US$272.98
by 24 Nov 2026
Projected move
6.0%
gross, before costs
Price sits between our buy level and our target.
On this stock's own history these rules produced 6 settled calls, of which 2 reached target (33.3%), with an average best move of 4.8%. See the full record.
- Upper line touches
- 3
- Lower line touches
- 3
- Fit confidence
- 85%
- Fitted
- 15 Sept 2026
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato
- Employees
- 141,700
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- 35/100
- Profitability
- 82/100
- Financial health
- 64/100
- Cash generation
- 49/100
Key statistics
- Market cap
- US$645.95B
- Enterprise value
- US$674.56B
- Beta
- 0.23
- Avg volume
- 7.79M
- Revenue per share
- 40.13
- Dividend yield
- 1.97%
- 52-week range
- 173.33-276.47
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 30.99
- PEG
- -3.84
- Price / sales
- 6.60
- Price / book
- 7.70
- EV / EBITDA
- 20.00
- Gross margin
- 70.45%
- Operating margin
- 26.81%
- Net margin
- 21.48%
- Current ratio
- 1.09
- Quick ratio
- 0.81
- Debt / equity
- 0.58
- Interest cover
- 25.94
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$94.19B | US$68.56B | US$25.60B | US$26.80B | US$11.03 |
| 2024 | US$88.82B | US$61.35B | US$22.15B | US$14.07B | US$5.79 |
| 2023 | US$85.16B | US$58.61B | US$23.41B | US$35.15B | US$13.72 |
| 2022 | US$79.99B | US$55.39B | US$21.01B | US$17.94B | US$6.73 |
| 2021 | US$78.74B | US$55.34B | US$20.94B | US$20.88B | US$7.81 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$199.21B | US$117.67B | US$81.54B |
| 2024 | US$180.10B | US$108.61B | US$71.49B |
| 2023 | US$167.56B | US$98.78B | US$68.77B |
| 2022 | US$187.38B | US$110.57B | US$76.80B |
| 2021 | US$182.02B | US$108.00B | US$74.02B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$24.53B | US$19.70B | US$26.80B |
| 2024 | US$24.27B | US$19.84B | US$14.07B |
| 2023 | US$22.79B | US$18.25B | US$13.33B |
| 2022 | US$21.19B | US$17.18B | US$17.94B |
| 2021 | US$23.41B | US$19.76B | US$20.88B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$10.80 | US$93.76B | 17 |
| 2026 | US$11.59 | US$101.24B | 4 |
| 2027 | US$12.75 | US$108.64B | 4 |
| 2028 | US$14.25 | US$117.11B | 5 |
| 2029 | US$16.18 | US$125.20B | 1 |
| 2030 | US$18.05 | US$134.64B | 1 |
Analyst view
- Target (mean)
- US$282.08
- Target (high)
- US$305.00
- Target (low)
- US$255.00
- Strong buy
- 0
- Buy
- 21
- Hold
- 16
- Sell
- 3
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.